OUTLOOK Interest Debt Per Share from 2010 to 2024

OTLK Stock  USD 2.01  0.31  18.24%   
OUTLOOK THERAPEUTICS Interest Debt Per Share yearly trend continues to be quite stable with very little volatility. The value of Interest Debt Per Share is projected to decrease to 94.57. From the period between 2010 and 2024, OUTLOOK THERAPEUTICS, Interest Debt Per Share regression line of its data series had standard deviation of  103.46 and standard deviation of  103.46. View All Fundamentals
 
Interest Debt Per Share  
First Reported
2010-12-31
Previous Quarter
186.2541285
Current Value
94.57
Quarterly Volatility
103.45991371
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check OUTLOOK THERAPEUTICS financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among OUTLOOK THERAPEUTICS's main balance sheet or income statement drivers, such as Depreciation And Amortization of 37.8 K, Interest Expense of 3.3 T or Selling General Administrative of 31.4 T, as well as many indicators such as Price To Sales Ratio of 2.84, Dividend Yield of 12.5 K or Days Sales Outstanding of 190. OUTLOOK financial statements analysis is a perfect complement when working with OUTLOOK THERAPEUTICS Valuation or Volatility modules.
  
Check out the analysis of OUTLOOK THERAPEUTICS Correlation against competitors.

Latest OUTLOOK THERAPEUTICS's Interest Debt Per Share Growth Pattern

Below is the plot of the Interest Debt Per Share of OUTLOOK THERAPEUTICS INC over the last few years. It is OUTLOOK THERAPEUTICS's Interest Debt Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in OUTLOOK THERAPEUTICS's overall financial position and show how it may be relating to other accounts over time.
Interest Debt Per Share10 Years Trend
Slightly volatile
   Interest Debt Per Share   
       Timeline  

OUTLOOK Interest Debt Per Share Regression Statistics

Arithmetic Mean116.37
Geometric Mean38.70
Coefficient Of Variation88.91
Mean Deviation94.10
Median94.57
Standard Deviation103.46
Sample Variance10,704
Range235
R-Value(0.68)
Mean Square Error6,259
R-Squared0.46
Significance0.01
Slope(15.64)
Total Sum of Squares149,855

OUTLOOK Interest Debt Per Share History

2024 94.57
2023 186.25
2022 2.97
2021 1.17
2020 1.67
2019 1.74
2018 16.33

About OUTLOOK THERAPEUTICS Financial Statements

OUTLOOK THERAPEUTICS investors utilize fundamental indicators, such as Interest Debt Per Share, to predict how OUTLOOK Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Interest Debt Per Share 186.25  94.57 

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether OUTLOOK THERAPEUTICS INC is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if OUTLOOK Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Outlook Therapeutics Inc Stock. Highlighted below are key reports to facilitate an investment decision about Outlook Therapeutics Inc Stock:
Check out the analysis of OUTLOOK THERAPEUTICS Correlation against competitors.
You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of OUTLOOK THERAPEUTICS. If investors know OUTLOOK will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about OUTLOOK THERAPEUTICS listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.06)
Revenue Per Share
0.119
Quarterly Revenue Growth
6.583
Return On Assets
(0.84)
Return On Equity
(0.04)
The market value of OUTLOOK THERAPEUTICS INC is measured differently than its book value, which is the value of OUTLOOK that is recorded on the company's balance sheet. Investors also form their own opinion of OUTLOOK THERAPEUTICS's value that differs from its market value or its book value, called intrinsic value, which is OUTLOOK THERAPEUTICS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because OUTLOOK THERAPEUTICS's market value can be influenced by many factors that don't directly affect OUTLOOK THERAPEUTICS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between OUTLOOK THERAPEUTICS's value and its price as these two are different measures arrived at by different means. Investors typically determine if OUTLOOK THERAPEUTICS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, OUTLOOK THERAPEUTICS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.